TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

2013-10

Moretti, Erica
Desmedt, Christine
Biagioni, Chiara
Regan, Meredith M
Oakman, Catherine
Larsimont, Denis
Galardi, Francesca
Piccart-Gebhart, Martine
Sotiriou, Christos
Rimm, David D.L.
Di Leo, Angelo

Anthracyclines are commonly used in breast cancer, although they lack validated predictive biomarkers. We explored the interaction between TOP2A protein by quantitative immunofluorescence (QIF) and anthracycline sensitivity.
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
info:eu-repo/semantics/published

Cancérologie; Médecine pathologie humaine; Sciences bio-médicales et agricoles; Antigens, Neoplasm -- genetics -- metabolism; Antineoplastic Agents -- therapeutic use; Breast Neoplasms -- drug therapy -- metabolism -- mortality; Cell Nucleus -- metabolism; Cytoplasm -- metabolism; DNA Topoisomerases, Type II -- genetics -- metabolism; DNA-Binding Proteins -- genetics -- metabolism; Epirubicin -- therapeutic use; Female; Humans; Immunohistochemistry; Neoadjuvant Therapy; Prognosis; Protein Transport; Topoisomerase II Inhibitors -- therapeutic use; anthracyclines; biomarker; breast cancer; quantitative immunofluorescence; TOP2A; info:eu-repo/semantics/article; info:ulb-repo/semantics/articlePeerReview; info:ulb-repo/semantics/openurl/article

No full-text files
English

EQY oai:dipot.ulb.ac.be:2013/153435
uri/info:doi/10.2217/fon.13.103
uri/info:pmid/24106899
uri/info:scp/84885635917
1363785247

UNIVERSITE LIBRE DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.

edsoai.on1363785247